Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9416347 | 0.77 | EPHX1 (0.39) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL939785 | 0.70 | ALDH1A1 (0.42) | EPHX1SHBGTP53ALDH1A1 | |
| SCHEMBL2768891 | 0.70 | ALDH1A1 (0.42) | EPHX1SHBGTP53ALDH1A1 | |
| SCHEMBL28571200 | 0.66 | ALDH1A1 (0.38) | EPHX1ALDH1A1 | |
| SCHEMBL995374 | 0.65 | EPHX1 (0.32) | EPHX1SHBGTP53 | |
| SCHEMBL28416887 | 0.65 | EPHX1 (0.32) | EPHX1SHBGTP53 | |
| SCHEMBL331898 | 0.65 | EPHX1 (0.32) | EPHX1SHBGTP53 | |
| SCHEMBL2844353 | 0.65 | EPHX1 (0.43) | EPHX1SHBGTP53KDM4EGMNN | |
| Iodide SCHEMBL28876916 | 0.64 | EPHX1 (0.31) | EPHX1SHBG | |
| SCHEMBL3227070 | 0.63 | EPHX1 (0.45) | EPHX1SHBGTP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-4411893-A | ENHANCED SKIN PENETRATION, WATER-SOLUBLE TERTIARY AMINE OXIDES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1983-10-25 | — | — | US | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-118948828-A | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118649239-A | Topical delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | 克里蒂泰克公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-110636833-B | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| US-6217852-B1 | APPLYING DURING WASHING; SUNSCREEN AGENT | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. | 2001-04-17 | — | — | US | disclosed |
| WO-2000009081-A1 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5731303-A | MACROCYCLIC COMPOUNDS ENHANCE DRUG ABSORPTION ACROSS BLOOD-BRAIN BARRIER | CONREX PHARMACEUTICAL CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0248885-B1 | TRANSDERMAL DELIVERY OF DRUGS | HSIEH, Dean (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5023252-A | Using heterocyclic oxygen, sulfur, or nitrogen containing compound | CONREX PHARMACEUTICAL CORPORATION (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0248885-A4 | TRANSDERMAL DELIVERY OF DRUGS. | HSIEH DEAN | 1988-05-16 | — | — | EP | disclosed |
| EP-0248885-A1 | TRANSDERMAL DELIVERY OF DRUGS. | HSIEH DEAN | 1987-12-16 | — | — | EP | disclosed |
| WO-1987003473-A1 | TRANSDERMAL DELIVERY OF DRUGS | HSIEH DEAN | 1987-06-18 | — | — | WO | disclosed |
| US-4411893-A | ENHANCED SKIN PENETRATION, WATER-SOLUBLE TERTIARY AMINE OXIDES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | EPHX1 2766/4885SHBG 2077/4885TP53 1/4885 |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | EPHX1 3452/4885SHBG 3271/4885TP53 3/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | EPHX1 3452/4885SHBG 3271/4885TP53 3/4885 |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | EPHX1 2766/4885SHBG 2077/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.